New guidelines for psychedelics trials aim to be ‘gold standard’
New psychedelic trial guidelines covering music, lighting, and cultural safety aim to set a global “gold standard” for clinical research.
Innovative trial will use psilocybin to target relapse in opioid addiction
Imperial researchers will explore the potential for psilocybin therapy in drug recovery as part of a landmark trial.
Psychedelic experiences linked with improved sexual function
Magic mushrooms, LSD and other psychoactive compounds may help to improve sexual function for months after the psychedelic experience.
Psychedelic therapy may help break the chains of gambling addiction
Researchers at Imperial’s Centre for Psychedelic Research are using brain imaging to understand addictions and devise new approaches to treating them.
Bendy X-rays and DMT infusions: News from Imperial
Here’s a batch of fresh news and announcements from across Imperial.
Audio
Podcast: Supersonic flight, toxic pet treatments, and fighting TB with maths
In this edition: The future of supersonic flight, how toxic flea and tick products are reaching the environment, and how maths can help eradicate TB.
Advanced brain imaging study hints at how DMT alters perception of reality
Scientists have gleaned new insights into how psychedelics alter conscious experience via their action on brain activity.
6 amazing scientific achievements at Imperial in 2022
From exploring magic mushrooms to answering COVID-19 questions, here are some of Imperial’s biggest findings this year:
Audio
Podcast: Making malaria history, psychedelics for depression and a new diet
In this edition: We discover what it will take to eradicate malaria, how psychedelics affect the depressed brain, and how a new diet can keep us full.
1
Magic mushroom compound increases brain connectivity in people with depression
Psilocybin, the psychedelic compound found in magic mushrooms, helps to “open up” depressed people’s brains, even weeks after use, a study has found.
4
